Patients with stroke | Controls | |||||
---|---|---|---|---|---|---|
HR | SD | p Value | HR | SD | p Value | |
Age | 1.087* | <0.001 | <0.001 | 1.114 | <0.001 | <0.001 |
Gender (female) | 0.786 | 0.016 | <0.001 | 0.679 | 0.017 | <0.001 |
Charlson comorbidity index | 1.076* | 0.014 | <0.001 | 1.403* | 0.014 | <0.001 |
SSRI (incl. SNRI) | 1.699* | 0.030 | <0.001 | 1.908 | 0.022 | <0.001 |
TCA | 1.365 | 0.045 | <0.001 | 1.733 | 0.060 | <0.001 |
BZD | 1.643* | 0.040 | <0.001 | 1.776* | 0.053 | <0.001 |
BZD-like drugs | 1.386 | 0.021 | <0.001 | 1.547 | 0.025 | <0.001 |
FGA | 2.001 | 0.076 | <0.001 | 3.361* | 0.159 | <0.001 |
SGA | 1.645 | 0.070 | <0.001 | 2.555 | 0.086 | <0.001 |
Observations | 49 968 | 86 100 | ||||
Per cent censored | 64.5 | 81.3 |
Bold typeface indicates p<0.001.
Time×interaction coefficient not reported.
Estimate=a+a_t×year.
*Time-varying covariates were calculated in year 2, when all time-dependent covariates were significant in the time test.
BZD, benzodiazepine; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.